Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 14/20 | 1.00 |
| ▸ | MGLL | Q99685 | 9/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420799 | 1.00 | FAAH (1.00) | FAAHMGLLKDM4EALDH1A1LMNA | |
| SCHEMBL30302127 | 0.93 | FAAH (0.87) | FAAHMGLLKDM4EALDH1A1LMNA | |
| SCHEMBL20566498 | 0.93 | FAAH (0.87) | FAAHMGLLKDM4EALDH1A1LMNA | |
| SCHEMBL25829910 | 0.92 | FAAH (0.84) | FAAHMGLLKDM4EALDH1A1LMNA | |
| SCHEMBL20566986 | 0.91 | FAAH (1.00) | FAAHMGLL | |
| SCHEMBL20567040 | 0.91 | FAAH (0.83) | FAAHMGLL | |
| SCHEMBL30420683 | 0.91 | FAAH (0.83) | FAAHMGLL | |
| SCHEMBL30420287 | 0.91 | FAAH (1.00) | FAAHMGLL | |
| SCHEMBL20567203 | 0.90 | FAAH (0.81) | FAAHMGLLKDM4EALDH1A1LMNA | |
| SCHEMBL30419972 | 0.90 | FAAH (0.81) | FAAHMGLLKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| EP-3630744-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-01-25 | — | — | EP | disclosed |
| US-20220031676-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-02-03 | — | — | US | disclosed |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2021-02-25 | — | — | US | disclosed |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2021-02-25 | — | — | US | disclosed |
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| WO-2020112905-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-10266497-B2 | Pyrazole MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266497-B2 | Pyrazole MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | FAAH 33/4885MGLL 1/4885KDM4E 3347/4885 |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | FAAH 33/4885MGLL 1/4885KDM4E 3347/4885 |
| US-10266497-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | FAAH 33/4885MGLL 1/4885KDM4E 3347/4885 |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | FAAH 33/4885MGLL 1/4885KDM4E 3347/4885 |
| US-20220031676-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | FAAH 67/4885MGLL 1/4885KDM4E 3190/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | FAAH 32/4885MGLL 1/4885KDM4E 2927/4885 |
| US-10927105-B1 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | FAAH 33/4885MGLL 1/4885KDM4E 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.